Corticosteroids, a commonly prescribed medication to alleviate cancer-related symptoms for non-small cell lung cancer ...

The treatment marks the only targeted oral treatment in patients with non–small cell lung cancer with epidermal growth factor ...

The FDA granted accelerated approval to the tyrosine kinase inhibitor sunvozertinib (Zegfrovy) for advanced non-small cell ...

In a primary efficacy population of 85 patients, the confirmed overall response rate was 46%.